Latest news and press releases about Organogenesis Holdings Inc. (ORGO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products.
Price
| Price | $1.39 |
| Market Cap | $179M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.62 |
| EV / EBITDA | -50.95 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -24.23% |
| Return on Invested Capital | -8.12% |
| Return on Assets | -22.20% |
| Gross Margin | 67.59% |
| Operating Margin | -6.38% |
| Net Margin | -19.76% |
Related companies: ANGO · BCYC · CMPX · EBS · EOLS · ESPR · MNPR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ORGO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks